OCT 31, 2018 08:00 AM PDT

Researchers identify a protein marker that induces dormancy in metastatic breast cancer

Researchers at the Mount Sinai hospital identified for the first time, a protein marker that could indicate whether breast cancer will further metastasize or remain in a dormant state, according to a clinical study published in Breast Cancer Research this month.

Breast cancer patients can relapse and die from the disease years after their primary treatment, which indicated that some of the tumor cells, called disseminated tumor cells (DTCs), remain in a dormant state with no or slow proliferation, with the ability to progress and proliferate later. However, studies also showed that 60% of DTC-positive patients did not relapse. Therefore, there was a need for more studies to understand the biology behind this dormancy behavior.

Disseminated tumor cells are cancer cells that have left the primary tumor and survived in the circulation to land in a distant organ. Credit:https://www.kennethjpienta.com

This new research showed that when DTCs metastasize from their original tumor into the patients bone marrow, with no or a small amount of the protein receptor NR2F1, the patient relapse and soon dies. Patients who had a higher concentration of NR2F1 in their DTCs did not develop metastasis and survived longer. The higher concentration of NR2F1 induced the dormancy state, deactivating cancer cells and preventing metastasis.

These findings suggest that NR2F1 concentration can be used as an indicator of whether there is a possibility for tumor metastasis requiring additional treatments, or if the cancer cells will remain dormant which will save the patient from unnecessary treatments.

This research was a collaboration between Mount Sinai researchers and physicians in Oslo, Norway, where bone marrow tests called aspirates, which are not used in the US, are used to monitor patients.

“Improved techniques to assess the population of patients with residual disease and their dormant or reactivating state will be key to identifying the risk of future metastasis despite undergoing standard treatment. This opens the way for testing new treatments that prevent metastasis by inducing dormancy or eradicating the dormant disseminated cancer cells that have not yet initiated metastatic growth,” said lead researcher, Julio Aguirre-Ghiso, PhD, Director of Solid Tumor and Metastasis Research, Director of Head and Neck Cancer Basic Research, and Professor of Oncological Sciences, Otolaryngology, and Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.

Earlier studies showed that higher concentrations of NR2F1 are induced in response to androgen deprivation treatment, an anti-hormone treatment used in prostate cancer, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai will soon start a new clinical study testing the ability of two drugs to induce dormancy through upregulation of NR2F1 in prostate cancer patients.

Source: Sciencedaily via Mount Sinai

About the Author
  • A master student in Biochemistry and Molecular biology with experience in Education and Research. I am passionate about scientific research and passing my knowledge to others to help them learn about the latest in science by teaching, writing and volunteering in scientific events.
You May Also Like
JUN 27, 2018
Infographics
JUN 27, 2018
The Role of Biomarkers In Modern Medicine
A biomarker (short for biological marker) is a measurable indicator of some biological state or condition. The biomarker can be measured objectively and consistently. Biomarkers play signific...
JUN 27, 2018
Cell & Molecular Biology
JUN 27, 2018
Finding a new way to Stop the Growth of Cancer
Scientists discovered something new about the behavior of an organelle called ribosomes in cancer cells....
JUL 18, 2018
Immunology
JUL 18, 2018
Immunotherapy Increases Survival of Melanoma Brain Metastases Patients
Use of Checkpoint Blockade Immunotherapy increases survival rates in Melanoma Brain Metastases patients, with a 4-year survival rate increase from 11.1% to 28.1%...
AUG 07, 2018
Cancer
AUG 07, 2018
Is There a Best Time of Day to Administer Chemo?
A common hematologic cancer chemotherapy agent is looked at for its efficacy on solid tumors and specifically evaluates if delivery time during the day affects is anti-tumor activity....
SEP 20, 2018
Genetics & Genomics
SEP 20, 2018
Liquid Phase Separation may Play a Role in Cancer
Not all liquids mix, like oil and water; the phenomenon is called liquid-liquid phase separation. We're learning more about its role in cells....
SEP 26, 2018
Cancer
SEP 26, 2018
Rare Cancer the Focus of Mesothelioma Awareness Day
More than 2,500 Americans are diagnosed with mesothelioma cancer each year. The cancer is rare but very serious - most patients diagnosed with the disease live just a short 12 to 21 months....
Loading Comments...